Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00026663 · ClinicalTrials.gov registry record

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
86
Enrollment target

NCT00026663: Completed study, sponsored by National Cancer Institute (NCI).

NCT00026663 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00026663 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
86 participants
Enrollment target

Study Summary

This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings may provide information needed to develop methods of combating drug resistance. Patients with cancer who are 18 years or older may be eligible for this study. Participants will have 40 milliliters (3 tablespoons) of blood drawn at the beginning of the study; additional samples will be obtained periodically during the course of treatment. A small sample of tumor or normal tissue will be taken from patients who undergo surgery or tumor biopsy (removal of a small piece of tumor) for medical reasons or as part of a research treatment protocol. Patients who do not require surgery or biopsy may be asked permission to obtain a tumor sample. Depending on the location of the tumor, this may be done by: 1) withdrawing bone marrow through a small needle; 2) removing fluid from the chest or abdomen; 3) removing a small tumor sample through a needle; or 4) removing the sample with a small incision into or around the tumor. These procedures will be done only if they are of low risk to the patient.

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2000-08-09
Est. Completion 2024-06-28

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00026663

The ClinicalTrials.gov registry entry for NCT00026663 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00026663 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00026663 about?

NCT00026663 is a clinical study titled "Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance". This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to tre...

What is the current status of trial NCT00026663?

This trial is currently completed. The enrollment target is 86 participants. The study started on 2000-08-09. Estimated completion is 2024-06-28.

Who is sponsoring clinical trial NCT00026663?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.